Premium
Myo‐inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome
Author(s) -
Genazzani Alessandro D.,
Santagni Susanna,
Ricchieri Federica,
Campedelli Annalisa,
Rattighieri Erika,
Chierchia Elisa,
Marini Giulia,
Despini Giulia,
Prati Alessia,
Simoncini Tommaso
Publication year - 2014
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.12319
Subject(s) - medicine , endocrinology , polycystic ovary , luteinizing hormone , hyperinsulinemia , insulin , hormone , follicle stimulating hormone , insulin resistance
Aim To investigate hormonal dynamics in a group of non‐obese polycystic ovary syndrome ( PCOS ) patients under myo‐inositol ( MYO ) administration. Methods Hormonal profiles, insulin response to oral glucose tolerance test ( OGTT ) and luteinizing hormone ( LH ) response to gonadotropin‐releasing hormone ( GnRH ) stimulation test before and after the administration of a preparation of MYO (3 g p.o. daily) mixed with lactoferrin and bromelin, in a group ( n = 24) of normal weight PCOS patients. Results After the treatment interval, body mass index ( BMI ) did not change while LH , LH /follicle‐stimulating hormone, 17‐hydroxy‐progesterone and androstenedione decreased significantly. Insulin response to OGTT was significantly reduced after the treatment interval ( P < 0.05) as well as GnRH ‐induced LH response ( P < 0.05). High‐sensitivity C‐reactive protein decreased significantly after the treatment interval. Conclusion MYO administration positively modulates insulin sensitivity in non‐obese PCOS patients without compensatory hyperinsulinemia, improving hormonal parameters. The presence of bromelin in the formulation modulated the pro‐inflammatory state that characterizes PCOS , independently of BMI .